The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.

Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment. A method and dosing regimen is also described for delivery across the mucosa of the oral cavity for maximizing absorption and delivery, limiting systemic exposure and unwanted side effects, effectuating a sustained increase in concentrations of sex hormones and providing a non-invasive delivery that does not require inpatient visits. The method described benefits conditions such as hypogonadism in men due to aging or disease and symptoms related to menopause in women.

Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment. A method and dosing regimen is also described for delivery across the mucosa of the oral cavity for maximizing absorption and delivery, limiting systemic exposure and unwanted side effects, effectuating a sustained increase in concentrations of sex hormones and providing a non-invasive delivery that does not require inpatient visits. The method described benefits conditions such as hypogonadism in men due to aging or disease and symptoms related to menopause in women.

Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.

Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.

This disclosure provides method of treatment comprising administering an AQGV peptide, or a functional analog thereof, to a human subject, the human subject optionally having impaired kidney function, wherein the treatment of administering an AQGV peptide comprises maintaining or improving hemodynamic stability in the human subject, such as a human subject suffering or considered suffering from Clarkson's disease (CLS).

An infusion pump is disclosed comprising control unit, container, actuation unit and detection unit. The container can store medicinal liquid for treating hypogonadotropic hypogonadism. The control unit can receive external control signal comprising infusion interval, concentration of medicinal liquid and dose of medicament for treating hypogonadotropic hypogonadism at each infusion. The control unit is configured to activate actuation unit based on infusion interval to cause medicinal liquid to flow out of container. The detection unit can detect output of medicinal liquid from container and feed it back to control unit. The control unit is configured to activate actuation unit based on dose at each infusion, concentration of medicinal liquid and fed-back output of medicinal liquid. According to the invention, sustained, automatic infusions of the medicament for treating hypogonadotropic hypogonadism are allowed without patient intervention. As a result, intelligent infusion of medicament is achieved in an easy and efficient manner.

An infusion pump is disclosed comprising control unit, container, actuation unit and detection unit. The container can store medicinal liquid for treating hypogonadotropic hypogonadism. The control unit can receive external control signal comprising infusion interval, concentration of medicinal liquid and dose of medicament for treating hypogonadotropic hypogonadism at each infusion. The control unit is configured to activate actuation unit based on infusion interval to cause medicinal liquid to flow out of container. The detection unit can detect output of medicinal liquid from container and feed it back to control unit. The control unit is configured to activate actuation unit based on dose at each infusion, concentration of medicinal liquid and fed-back output of medicinal liquid. According to the invention, sustained, automatic infusions of the medicament for treating hypogonadotropic hypogonadism are allowed without patient intervention. As a result, intelligent infusion of medicament is achieved in an easy and efficient manner.

The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.

The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.